Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
What the film says
Multiple myeloma remains incurable, and responses to CAR T therapy aimed at one target, BCMA, often do not last.
The idea: aim CAR T cells at a different target, CS1, also called SLAMF7, which is found in most patients with myeloma. The patient's own T cells are collected and engineered with a CS1 receptor. They are returned after three days of chemotherapy that lowers existing lymphocytes. Patients stay in the hospital for seven days.
This early study looks at safety first, and at early signs of effect. At Washington University in St. Louis, Armin Ghobadi leads it.
Public record; not medical advice.
Sources behind this film
Myeloma remains incurable; BCMA CAR T responses often do not last; CS1 (SLAMF7) found in most patients; Own T cells collected and engineered with a CS1 receptor; Returned after three days of chemotherapy that lowers existing lymphocytes; seven days in hospital (+2 more lines)
The drug
-Subject will be hospitalized for 7 days
* Cyclophosphamide 500 mg/m^2 IV on Days -5, -4, and -3 * Fludarabine 30 mg/m^2 IV on Days -5, -4, and -3
CAR-T cells are an ideal modality to target CS1, given that two approved treatments, ide-cel (idecabtagene vicleucel, AbecmaTM) and cilta-cel (ciltacabtagene autoleucel, Carvykti™), have proven the potential for cellular immunotherapy in MM. The investigators are testing the safety and preliminary anti-myeloma efficacy of WS-CART-CS1, a CAR-T cell therapy targeting CS1.
The study
Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-targeting CAR-T cells show impressive response rates; however, their median duration of response is disappointing.
The investigators propose that CS1(SLAMF7)-targeting CAR-T cells will fill a gap in the MM armamentarium. CS1 is an attractive target in MM because it is expressed in most patients. Elotuzumab (Empliciti®), an approved anti-CS1 antibody, has proven the clinical efficacy of this target.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.